Welcome to EQL Pharma's Investor Pages!

We strive to have an open and proactive dialogue with our shareholders.

34.60 SEK

To Stock Graph

0.00 (0.00%)

Spotlight Stock Market

Annual Report 2022/2023Read Here

"Our portfolio grows from 26 to 28 products"

Listen to CEO Axel Schörling present EQL Pharma's latest report (in Swedish)

Interim Report Q2 2023/2024

Press Releases

2023-11-20

EQL Pharma again appointed Gazelle company in Skåne by Dagens Industri and once again places itself in 6th place out of 98 Skåne Gazelles

Every year, Dagens Industri appoints Sweden's fastest growing company to the so-called Gazelle company. It is an award to support and encourage Swedish entrepreneurs to grow.

2023-11-17

Interim Report April - September 2023

Regulatory

Growth despite large impact from the global antibiotics shortage, several important MA approvals and expansion of pipeline

2023-11-06

Invitation to presentation in connection with EQL Pharma's quarterly report, second quarter, 2023/24

EQL Pharma AB (publ) will publish its quarterly report for the second quarter, 2023/24, on Friday, November 17[th], before stock markets opening.

Se all

EQL Pharma in Short

EQL Pharma is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain in order to be able to deliver cost-efficient medicines of highest quality to pharmacies and hospitals.